2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Amino acid Transporter
  5. Amino acid Transporter Inhibitor

Amino acid Transporter Inhibitor

Amino acid Transporter Inhibitors (16):

Cat. No. Product Name Effect Purity
  • HY-120139
    KMH-233
    		Inhibitor 99.75%
    KMH-233, a potent, reversible and selective inhibitor of l-type amino acid transporter LAT1/SLC7A5, inhibits the uptake of LAT1 substrate, l-leucin (IC50=18 μM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 μM).
  • HY-156682
    JNT-517
    		Inhibitor 99.00%
    JNT-517 is an orally active, selective SLC6A19 allosteric inhibitor with an IC50 of 47 nM for human SLC6A19. JNT-517 can be used for the study of phenylketonuria (PKU).
  • HY-B1274
    Cinromide
    		Inhibitor 99.83%
    Cinromide is an anticonvulsant agent. Cinromide inhibits epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 of 0.5 μM.
  • HY-179581
    SLC6A19-IN-4
    		Inhibitor 99.55%
    SLC6A19-IN-4 is an allosteric-competitive and orally active B0AT1 inhibitor. SLC6A19-IN-4 inhibits both human and mouse B0AT1 with IC50 values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine (Phe) excretion and reduces plasma Phe levels through dual inhibition of B0AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6-family transporters research.
  • HY-112005G
    DOPE (GMP)
    		Inhibitor
    DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.
  • HY-161137
    LQFM215
    		Inhibitor 99.80%
    LQFM215 is a proline transporter (PROT) inhibitor. LQFM215 inhibits proline transport by competitively binding to the active site of PROT. LQFM215 effectively reduces hyperlocomotion and enhances social interaction.
  • HY-162864
    JX237
    		Inhibitor 98.84%
    JX237 is an inhibitor of the epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 value of 31 nM. SLC6A19 is the main transporter for the absorption of neutral amino acids in the intestines and their reabsorption in the kidneys. By inhibiting B0AT1, JX237 can be used for the study of disorders of amino acid metabolism.
  • HY-153763
    PROT-IN-1
    		Inhibitor 98.0%
    PROT-IN-1 is a PROT inhibitor (IC50: 1.48 μM). PROT-IN-1 is applicable to research related to cognitive impairment.
  • HY-176719
    AKR1B1/STAT3/SLC7A11-regulator-1
    		Inhibitor
    AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is an AKR1B1/STAT3/SLC7A11 regulator that reverses DOX resistance in MCF-7/ADR cells by enhancing ferroptosis activity. AKR1B1/STAT3/SLC7A11-regulator-1 can be used in breast cancer research.
  • HY-179107
    SLC6A19-IN-3
    		Inhibitor
    SLC6A19-IN-3 (Compound 83-P1-P2) is a potent, selective and orally active SLC6A19 inhibitor with an IC50 of 28 nM. SLC6A19-IN-3 can block SLC6A19-mediated transmembrane transport of phenylalanine, reducing intestinal absorption of phenylalanine from food and renal tubular reabsorption of phenylalanine. SLC6A19-IN-3 can be used for the research of metabolic disease, such as phenylketonuria.
  • HY-158161
    SLC6A19-IN-1
    		Inhibitor
    SLC6A19-IN-1 is a potent and highly selective inhibitor and transport corrector of human SLC6A19 (IC50=47 nM). Furthermore, at a concentration of 35 μM, SLC6A19-IN-1 exhibits no activity against SLC1A5, SLC7A5, or SLC6A8. SLC6A19-IN-1 is applicable to research on phenylketonuria (PKU) and hyperphenylalaninemia. SLC6A19-IN-1 is also suitable for studies related to various metabolic disorders, including tyrosinemia, maple syrup urine disease, urea cycle disorders, and hyperammonemia.
  • HY-117251
    LP-403812
    		Inhibitor
    LP-403812 is a high affinity proline transporter (PROT) inhibitor that produces dose-dependent inhibition of hPROT (IC50=0.11 μM; Ki=0.12 μM) and also inhibits the activity of mouse brain synaptosomal mPROT with the same potency (IC50=0.23 μM). LP-403812 can be used to study the function of PROT in the brain.
  • HY-W695425
    Creatine transporter-IN-1
    		Inhibitor
    Creatine transporter-IN-1 is a synthetic creatine transporter (CT1/SLC6A8) inhibitor. Creatine transporter-IN-1 inhibits creatine uptake and shows anticancer activity against cancer cells.
  • HY-113745
    LX-6171
    		Inhibitor
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
  • HY-176873
    SLC6A19-IN-2
    		Inhibitor
    SLC6A19-IN-2 (Example 4) is a potent SLC6A19 inhibitor with an IC50 of 14 nM. SLC6A19-IN-2 can be used for the study of metabolic diseases such as nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD) and phenylketonuria (PKU).
  • HY-179689
    SLC6A19-IN-5
    		Inhibitor
    SLC6A19-IN-5 (Example 25) is a SLC6A19 inhibitor with an IC50 of 11 nM. SLC6A19-IN-5 can be used for research on diseases related to abnormal amino acid metabolism, amino acid transport, and/or amino acid levels.